WARNING: This product is for research use only, not for human or veterinary use.
Hodoodo CAT#: H528809
CAS#: 26328-11-0
Description: Espindolol is a β-adrenoceptor antagonist potentially for the treatment of cachexia related to cancer.
Hodoodo Cat#: H528809
Name: Espindolol
CAS#: 26328-11-0
Chemical Formula: C14H20N2O2
Exact Mass: 248.15
Molecular Weight: 248.320
Elemental Analysis: C, 67.72; H, 8.12; N, 11.28; O, 12.89
Synonym: AGI-001; MT-102; AGI001; MT102; AGI 001; MT 102; Espindolol; (S)-(-)-Pindolol.
IUPAC/Chemical Name: (S)-1-((1H-indol-4-yl)oxy)-3-(isopropylamino)propan-2-ol
InChi Key: JZQKKSLKJUAGIC-NSHDSACASA-N
InChi Code: InChI=1S/C14H20N2O2/c1-10(2)16-8-11(17)9-18-14-5-3-4-13-12(14)6-7-15-13/h3-7,10-11,15-17H,8-9H2,1-2H3/t11-/m0/s1
SMILES Code: O[C@@H](CNC(C)C)COC1=CC=CC2=C1C=CN2
Appearance: Solid powder
Purity: >98% (or refer to the Certificate of Analysis)
Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility: Soluble in DMSO
Shelf Life: >2 years if stored properly
Drug Formulation: This drug may be formulated in DMSO
Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code: 2934.99.9001
More Info:
| Biological target: | |
| In vitro activity: | |
| In vivo activity: |
The following data is based on the product molecular weight 248.32 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.
| Concentration / Solvent Volume / Mass | 1 mg | 5 mg | 10 mg |
|---|---|---|---|
| 1 mM | 1.15 mL | 5.76 mL | 11.51 mL |
| 5 mM | 0.23 mL | 1.15 mL | 2.3 mL |
| 10 mM | 0.12 mL | 0.58 mL | 1.15 mL |
| 50 mM | 0.02 mL | 0.12 mL | 0.23 mL |
| Formulation protocol: | |
| In vitro protocol: | |
| In vivo protocol: |
1: Pötsch MS, Tschirner A, Palus S, von Haehling S, Doehner W, Beadle J, Coats AJ, Anker SD, Springer J. The anabolic catabolic transforming agent (ACTA) espindolol increases muscle mass and decreases fat mass in old rats. J Cachexia Sarcopenia Muscle. 2014 Jun;5(2):149-58. doi: 10.1007/s13539-013-0125-7. Epub 2013 Nov 22. PubMed PMID: 24272787; PubMed Central PMCID: PMC4053568.
2: Lainscak M, Laviano A. ACT-ONE - ACTION at last on cancer cachexia by adapting a novel action beta-blocker. J Cachexia Sarcopenia Muscle. 2016 Sep;7(4):400-2. doi: 10.1002/jcsm.12136. Epub 2016 Aug 5. PubMed PMID: 27625919; PubMed Central PMCID: PMC5011815.
3: Stewart Coats AJ, Ho GF, Prabhash K, von Haehling S, Tilson J, Brown R, Beadle J, Anker SD; for and on behalf of the ACT‐ONE study group.. Espindolol for the treatment and prevention of cachexia in patients with stage III/IV non-small cell lung cancer or colorectal cancer: a randomized, double-blind, placebo-controlled, international multicentre phase II study (the ACT-ONE trial). J Cachexia Sarcopenia Muscle. 2016 Jun;7(3):355-65. doi: 10.1002/jcsm.12126. Epub 2016 Jul 1. PubMed PMID: 27386169; PubMed Central PMCID: PMC4929828.
4: Morley JE, von Haehling S, Anker SD. Are we closer to having drugs to treat muscle wasting disease? J Cachexia Sarcopenia Muscle. 2014 Jun;5(2):83-7. doi: 10.1007/s13539-014-0149-7. Epub 2014 May 28. PubMed PMID: 24865381; PubMed Central PMCID: PMC4053564.
5: Ebner N, Steinbeck L, Doehner W, Anker SD, von Haehling S. Highlights from the 7th Cachexia Conference: muscle wasting pathophysiological detection and novel treatment strategies. J Cachexia Sarcopenia Muscle. 2014 Mar;5(1):27-34. doi: 10.1007/s13539-014-0136-z. Epub 2014 Mar 5. PubMed PMID: 24595460; PubMed Central PMCID: PMC3953317.
